Objective-Vascular inflammation is a key feature of both micro-and macrovascular complications in diabetes. Several lines of evidence have implicated the cytokine tumor necrosis factor (TNF)␣ as an important mediator of inflammation in diabetes. In the present study we evaluated the role of TNF␣ in streptozotocin (STZ)-induced diabetes on vascular inflammation in C57BL/6 wild-type and apoE Ϫ/Ϫ mice.
C omplications affecting the macro-and microvasculature are the major causes of mortality and morbidity among diabetic subjects. 1 The biological mechanisms involved in the development of diabetic vascular complication remain to be fully understood, but considerable attention has been paid to the triad of endothelial dysfunction, oxidative stress, and inflammation. 2, 3 One molecule that has been implicated in all of these conditions is the cytokine TNF␣. 4 TNF␣ plays a key role in initiating and modulating inflammatory responses including the regulation of other cytokines, adhesion molecules, and matrix metalloproteinases. 5, 6 It is expressed by vascular tissue in response to lipoprotein oxidation 7 and by cultured macrophages exposed to oxidized low-density lipoprotein (LDL). 8 TNF␣ is expressed in atherosclerotic plaques 9, 10 and has been found to be associated with atherosclerosis and cardiovascular events in epidemiological studies. [11] [12] [13] Experimental studies have demonstrated that TNF␣deficient hypercholesterolemic mice, as well as mice treated with TNF␣ inhibitors, develop less atherosclerosis. 14, 15 TNF␣ has also been shown to be involved in the development of insulin resistance. 16 Plasma levels of TNF␣ are increased in patients with both type 1 and type 2 diabetes and are significantly correlated to elevated fasting glucose levels, glycohemoglobin (HbA 1c ), and markers of oxidative stress. 17, 18 Taken together these studies provide strong indirect support for a functional role of TNF␣ in the development of vascular complications in diabetes. To investigate this possibility we studied the development of early atherosclerotic changes in large arteries, as well as endothelial activation in resistance cerebral arteries, in C57BL/6 wild-type, apoE Ϫ/Ϫ , TNF␣ Ϫ/Ϫ , apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ , and infliximab (TNF␣-antibody)-treated apoE Ϫ/Ϫ mice made hyperglycemic with streptozotocin (STZ).
Methods

Animals
All animal experiments had been approved by the local Animal Care and Use Committee. C57BL/6 wild type, apoE Ϫ/Ϫ were purchased from Taconic and TNF␣ Ϫ/Ϫ (B6,129-Tnf tmlGkl ) from the Jackson Laboratory (Bar Harbor, Maine). TNF␣ Ϫ/Ϫ and apoE Ϫ/Ϫ were intercrossed, and F7 TNF␣ Ϫ/Ϫ and F10 apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ progeny were used in the experiments. All animals were fed normal chow diet and tap water without restrictions. The number of mice included in the studies were 28 C57BL/6 wild-type ( 
Induction of Diabetes
At 22 weeks of age C57BL/6 wild-type, apoE Ϫ/Ϫ , TNF␣ Ϫ/Ϫ , and apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ mice were injected ip with STZ (60 mg in citrate buffer per kg body weight, ph 4.5) or vehicle once a day for 5 days. The animals were weighed once a week, and animals with a loss of body weight Ͼ10% were excluded from the study (2 C57BL/6 wild-type, 1 TNF␣ Ϫ/Ϫ , and 4 apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ mice). Blood glucose levels were measured using a One-Touch glucometer (LifeScan Inc). After 8 weeks, the animals were anesthetized with 300 L of a mixture containing distilled water, Hypnorm, and Dormicum (2:1:1, administered ip) and euthanized by exsanguination through cardiac puncture. Methods for tissue handling, immunofluorescence, immunohistochemistry, analysis of aortic atherosclerosis as well as serum cholesterol, triglyceride, and cytokine analyses are described in the supplemental materials (available online at http://atvb.ahajournals.org).
Statistics
Results are expressed as meansϮSEM if not otherwise specified. Statistical analysis was performed using GraphPad software (Prism 4.0) or SPSS version 12.0.1. Analyses of distributions were performed before decisions were made to use parametric or nonparametric tests. Statistical significance was determined using Student t test; Kruskal-Wallis followed by Dunn multiple comparison test or Mann-Whitney for nonparametric data; or 1-way ANOVA followed by Bonferroni or Tukey-Kramer post hoc tests for comparisons between Յ5 and Ն6 groups, respectively. (*PϽ0.05, **PϽ0.01, and ***PϽ0.001). Pearson test was used for correlation analyses.
Results
Effects on Glucose, Body Weight, Plasma Lipids, and Cytokines
C57BL/6 wild-type, apoE Ϫ/Ϫ , TNF␣ Ϫ/Ϫ , apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ , and infliximab-treated apoE Ϫ/Ϫ mice were chow-fed until 22 weeks of age, injected with STZ or vehicle once a day for 5 days and then kept on chow diet for another 8 weeks. STZ increased blood glucose levels by at least 2-fold in all groups ( Figure 1A ). At the time mice were euthanized, diabetic TNF␣ Ϫ/Ϫ and apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ mice had lower body weight than nontreated littermates ( Figure 1B ). In accordance with previous observations 19, 20 STZ-induced hyperglycemia was found to increase plasma cholesterol levels in apoE Ϫ/Ϫ mice ( Figure 1C ). Interestingly, an even more pronounced increase in plasma cholesterol was observed in apoE Ϫ/Ϫ mice also deficient for TNF␣. Cholesterol levels remained low in wild-type and TNF␣ Ϫ/Ϫ mice ( Figure 1C ). Triglyceride levels were higher in both infliximab-treated groups ( Figure  1D ). Accordingly, diabetic apoE Ϫ/Ϫ , apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ , and infliximab-treated apoE Ϫ/Ϫ mice had combined hyperglycemia and hyperlipidemia, whereas wild-type and TNF␣ Ϫ/Ϫ diabetic mice were characterized by hyperglycemia and no significant changes in plasma lipids. Plasma cytokine levels in C57BL/6 wild type and apoE Ϫ/Ϫ are presented in supplemental Tables I and II . Increased plasma levels of the keratinocyte-derived chemokines (KC, also known as CXCL1) was found in diabetic TNF␣ Ϫ/Ϫ , apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ , but not in diabetic infliximab-treated apoE Ϫ/Ϫ mice.
Effects of Hyperglycemia on Atherosclerosis
Atherosclerosis was assessed by en face Oil Red O staining of the descending aorta as well as by determining crosssectional plaque area at the aortic root. Only very minor Oil Red O staining was observed in control and diabetic C57BL/6 wild type, and no mice in these groups had atherosclerotic plaques exceeding 0.5% of the total surface of the descending aorta ( Figure 2A ). The presence of Oil Red O-stained plaques among TNF␣ Ϫ/Ϫ mice was more variable, with 2 mice in the TNF␣ Ϫ/Ϫ control group and 4 mice in the diabetic TNF␣ Ϫ/Ϫ group having more than 0.5% plaque staining. There was no significant difference in aortic atherosclerosis between TNF␣ Ϫ/Ϫ control and diabetic mice, but hyperglycemic TNF␣ Ϫ/Ϫ mice had more aortic atherosclerosis than hyperglycemic C57BL/6 wild-type mice (0.55Ϯ0.21% versus 0.02Ϯ0.04%, PϽ0.005). No plaques were detected in the aortic root of control or diabetic C57BL/6 wild-type and TNF␣ Ϫ/Ϫ mice (data not shown).
In accordance with previous studies, 14, 15 apoE Ϫ/Ϫ / TNF␣ Ϫ/Ϫ mice had fewer Oil Red O-stained plaques in the aorta than apoE Ϫ/Ϫ mice (0.97Ϯ0.60% versus 2.11Ϯ2.09%), but this difference was not statistically significant in the present study because ofna large variation in staining in the apoE Ϫ/Ϫ group ( Figure 2B ). Diabetes had no significant effect on atherosclerosis in the descending aorta in apoE Ϫ/Ϫ mice, apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ , or infliximab-treated apoE Ϫ/Ϫ mice. Furthermore, no significant difference in aortic root plaque area between apoE Ϫ/Ϫ , apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ , and infliximab-treated apoE Ϫ/Ϫ mice was observed, and no effect of diabetes on aortic root plaque size was found in any of the groups ( Figure 2C ).
Increased inflammation is believed to be a key mechanism in diabetic-induced vasculopathy. The inflammatory response of the aorta was assessed by immunohistochemical staining of macrophages in aortic root lesions. Diabetes resulted in increased macrophage accumulation in aortic root plaques of apoE Ϫ/Ϫ mice (10.5Ϯ3.1% versus 13.3Ϯ2.4%, PϽ0.01). Increased plaque inflammation in response to hyperglycemia was observed also in apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ and infliximabtreated apoE Ϫ/Ϫ mice ( Figure 3A and 3B) . Interestingly, the accumulation of macrophages was higher in diabetic apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ mice and infliximab-treated apoE Ϫ/Ϫ mice than in diabetic apoE Ϫ/Ϫ mice (19.7Ϯ4.2% and 28.3Ϯ6.4% versus 13.3Ϯ2.4%, PϽ0.001 and PϽ0.001, respectively). Moreover, more macrophages were found to accumulate in lesions of control apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ and control infliximab-treated apoE Ϫ/Ϫ mice than in control apoE Ϫ/Ϫ mice (14.9Ϯ5.2% and 19.4Ϯ5.0% versus 10.5Ϯ3.1%, PϽ0.02 and PϽ0.001, respectively). There were significant associations between the macrophage accumulation in subvalvular plaques and the plasma levels of glucose and cholesterol in apoE Ϫ/Ϫ mice (rϭ0.41, PϽ0.05 and 0.84, PϽ0.001 respectively; both control and STZ mice were included in the analyses). The association between plasma glucose and plaque macrophage accumulation was even stronger in apoE Ϫ/Ϫ mice lacking TNF␣ (rϭ0.57, Pϭ0.001), although the association was weaker for plaque macrophages and plasma cholesterol (rϭ0.52, PϽ0.005). Hyperglycemia did not significantly affect VCAM-1 expression in subvalvular plaques (supplemental Figure I) .
Atherosclerosis is associated with accumulation of autoantibodies against oxidized LDL and other modified self antigens in plaque tissue. To analyze whether diabetes affected this process, aortic root lesions were stained for mouse IgG and IgM. There was no difference in IgG and IgM immunoreactivity between control and diabetic apoE Ϫ/Ϫ mice or between control and diabetic apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ mice (supplemental Figures II and III) . However, significantly higher IgG and IgM levels were found in lesions of control apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ mice than in lesions of apoE Ϫ/Ϫ mice (supplemental Figures II and III) .
Effects of Hyperglycemia on VCAM-1 Expression in Cerebral Arteries
To determine the effect of diabetes on inflammatory activation in small-to midsized arteries, we assessed the expression of VCAM-1 in cerebral arteries by confocal immunofluorescence microscopy. In accordance with previous studies, 21 a basal expression of VCAM-1 was detected in both endothelial and smooth muscle cells in intact cerebral arteries of control C57BL/6 wild-type mice. The expression was higher in endothelial cells than in smooth muscle cells and it was dependent on vessel diameter, with higher expression in the larger (Ͼ150 m) cerebral arteries ( Figure 4A and 4B ). TNF␣ Ϫ/Ϫ mice had overall lower endothelial and smooth muscle cell expression of VCAM-1 than C57BL/6 wild-type mice suggesting that TNF␣ Ϫ/Ϫ was involved in the basal regulation of VCAM-1 expression in these vessels. However, TNF␣ Ϫ/Ϫ mice also deficient for apoE Ϫ/Ϫ had a higher basal expression of VCAM-1, and there was no difference as compared to C57BL/6 wild-type mice ( Figure 5A and 5B) . The latter observation suggests that hyperlipidemia induces VCAM-1 expression in smaller arteries by a mechanism that is independent of TNF␣.
Diabetes enhanced VCAM-1 expression in cerebral arteries of apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ mice and to a lesser extent also in mice deficient for either TNF␣ or apoE, but not in infliximabtreated apoE Ϫ/Ϫ mice ( Figure 6 ). Induction of diabetes was found to reduce VCAM-1 expression in cerebral arteries of C57BL/6 wild-type mice ( Figure 5 and supplemental Figure  IV) . This reduction was observed in small (Ͻ100 m) and in the largest (Ͼ150 m) cerebral arteries (supplemental Figure  IV) , whereas the enhanced expression seen in apoE-deficient mice was more prominent in the largest (Ͼ150 m) vessels ( Figure 6A) . A significant association was found between blood glucose levels and endothelial VCAM-1 expression in apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ and TNF␣ Ϫ/Ϫ mice (rϭ0.53, PϽ0.05 and 0.58, PϽ0.05, respectively), but no such associations were observed in TNF␣-competent C57BL/6 wild-type or apoE Ϫ/Ϫ mice (both control and STZ mice were included in the analyses). There was no correlation between endothelial expression of VCAM-1 in cerebral arteries and plasma cholesterol or triglyceride levels.
Discussion
The present study confirms previous observations that diabetes enhances macrovascular inflammation in hyperlipidemic mice [22] [23] [24] [25] and extends these findings by demonstrating aggravated inflammation also in smaller vessels such as the cerebral arteries. The main focus of our study was to determine whether the vascular inflammatory response to hyperglycemia is mediated by TNF␣. Previous studies have demonstrated that TNF␣ is critically involved in the development of atherosclerotic lesions in hypercholesterolemic animals. 14, 15, 26, 27 TNF␣ has also been suggested to represent an important link between metabolic dysregulation and inflammation in diabetes, 4, 18, 28 and plasma levels of TNF␣ are increased in type 1 diabetes patients suffering from proliferative retinopathy. 29, 30 Collectively, these studies suggest that hyperglycemia or other metabolic changes associated with diabetes may contribute to the development of diabetic vasculopathy through TNF␣-induced vascular inflammation. However, in contrast to this notion the present findings clearly demonstrate that TNF␣ does not mediate vascular inflammation in response to hyperglycemia.
The present studies also reveal a complex role for TNF␣ in the regulation of vascular homeostasis and response to metabolic stress. In apoE-competent mice, TNF␣ appeared to have a protective effect on hyperglycemia-induced athero- sclerosis because TNF␣ Ϫ/Ϫ diabetic mice developed more lesions in the descending aorta than diabetic C57BL/6 wildtype mice. Moreover, TNF␣ also had a protective role against macrovascular inflammation because the macrophage content was higher in subvalvular lesions of apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ and infliximab-treated apoE Ϫ/Ϫ mice than in TNF␣-competent apoE Ϫ/Ϫ mice, irrespective of whether the mice were hyperglycemic or not. We also obtained evidence for a protective effect of TNF␣ on vascular inflammation in cerebral arteries. Although diabetes only induced a modest increase in VCAM-1 expression in cerebral arteries with a diameter Ͼ150 m in apoE Ϫ/Ϫ mice, this increase was much more prominent in cerebral arteries of apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ mice and affected also arteries with a diameter less than 150 m. The concept of a protective role of TNF␣ is further supported by the significant association between blood glucose levels and endothelial VCAM-1 expression in mice lacking TNF␣ Ϫ/Ϫ , whereas no such association was present in TNF␣-competent mice. Additional evidence for a protective role of TNF␣ in vascular inflammation came from the observation that although hyperglycemia actually decreased VCAM-1 expression in the cerebral arteries of C57BL/6 wild-type mice, it increased VCAM-1 expression in the absence of TNF␣. However, it should be noted that induction of hyperglycemia did not increase VCAM-1 expression in infliximab-treated apoE Ϫ/Ϫ mice, suggesting that the increased cerebral artery VCAM-1 expression observed in TNF␣ Ϫ/Ϫ mice may be driven by other alterations in the immune system than the actual absence of TNF␣ Ϫ/Ϫ . A number of studies have reported that TNF␣ deficiency in hypercholesterolemic mice results in reduction of atherosclerotic plaque size without decreasing the plaque content of inflammatory cells, 14, 26, 31 and in line with the present observations some of these studies even observed a trend toward increased plaque inflammation in TNF␣-deficient mice. The reason why a reduced plaque inflammation was less evident in previous studies remains to be fully clarified, but it is possible that the use of a proinflammatory high-fat diet (as opposed to the chow diet used in this study) masked any possible influence of TNF␣ deficiency in those studies.
TNF␣ is a key mediator of inflammatory responses able to target cells in the vascular wall. 5, 6 Because it activates the expression of a number of adhesion molecules, chemoattractants, and proinflammatory cytokines, the present observation of increased plaque inflammation in apoE Ϫ/Ϫ /TNF␣ Ϫ/Ϫ mice was unexpected. One possible explanation to the increased vascular inflammation in TNF␣-deficient mice described here is that they suffer from a more general dysregulation of the immune system. 32, 33 However, the finding of increased plaque inflammation also in infliximab-treated apoE Ϫ/Ϫ mice argue against this possibility and provide support for a direct antiinflammatory role of TNF␣ in these lesions. In mouse models of autoimmune demyelination, 34 autoimmune lupus nephritis, 35 and type I diabetes, 36 TNF␣ was found to protect animals from severe injury. Suggested mechanisms include transactivation of NF-B leading to the induction of antiapoptotic genes improving cell survival 37 and induction macrophage expression of alternative cytokine signaling including antiinflammatory cytokines such as IL-10 and TGF␤. 38, 39 Several previous studies have reported that STZ-induced hyperglycemia increases the development of atherosclerosis in apoE Ϫ/Ϫ mice. 22, 23, 40 The reasons for the lack of such an effect in our studies remain to be clarified but may involve differences in diet (ie, chow versus high fat) and duration of the study (ie, early versus late stages of atherosclerosis).
There are some limitations to the present study that need to be considered. It has not been entirely established that the mouse is a fully appropriate model for studies of vascular complications in diabetes. 19 Accordingly, although the present observations exclude TNF␣ as the mediator of diabetesinduced vascular inflammation in mice, they do not necessarily exclude that TNF␣ may be actively involved in the development of diabetic vascular complications in man. Another limitation of the present study is that the use of hyperglycemic apoE Ϫ/Ϫ mice does not allow us to differentiate whether the proinflammatory effect is induced by hyperglycemia or hyperlipidemia. However, it is of interest to note that whereas inflammation in the aorta correlated with cholesterol and glucose levels, inflammation in the smaller cerebral resistance arteries was only associated with plasma glucose and not lipid levels. Moreover, the association between vascular inflammation and plasma glucose levels was stronger in mice lacking TNF␣ again pointing to a paradoxical protective role of this cytokine in hyperglycemiainduced vascular inflammation.
In summary, these findings demonstrate that TNF␣ does not mediate diabetes-induced vascular inflammation in mice. They also show that TNF␣ deficiency is associated with a propensity to increased vascular inflammation and in particular in response to metabolic stress such as hyperglycemia or hyperlipidemia.
